Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154369 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TNFMAPTRAB9AALDH1A1 | |
| SCHEMBL6341030 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TNFMAPTRAB9AALDH1A1 | |
| SCHEMBL25753711 | 0.91 | L3MBTL1 (0.38) | L3MBTL1TNFMAPTRAB9AALDH1A1 | |
| SCHEMBL25752918 | 0.89 | L3MBTL1 (0.37) | L3MBTL1TNFMAPTRAB9AALDH1A1 | |
| SCHEMBL24036704 | 0.89 | L3MBTL1 (0.37) | L3MBTL1TNFMAPTRAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL30389457 | 0.88 | L3MBTL1 (0.36) | L3MBTL1TNFMAPTRAB9AALDH1A1 | |
| SCHEMBL25752836 | 0.85 | SLC13A3 (0.40) | L3MBTL1MAPTSMN1; SMN2LMNAGRN | |
| Hydrochloric Acid SCHEMBL30388827 | 0.84 | SLC13A3 (0.40) | L3MBTL1MAPTSMN1; SMN2LMNAGRN | |
| SCHEMBL24036568 | 0.84 | MAPT (0.37) | L3MBTL1TNFMAPTRAB9AALDH1A1 | |
| SCHEMBL4938396 | 0.84 | PNP (0.47) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| CN-111433207-B | As alpha V Pyrrolopyrazine derivatives of integrin inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| CN-110139864-B | Pyrrole amides as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-08-23 | — | — | CN | disclosed |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
| CN-110167933-A | Azole amides and amines as α V integrin inhibitors | 百时美施贵宝公司 | 2019-08-23 | — | — | CN | disclosed |
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| WO-2018089355-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089360-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089358-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256512-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | L3MBTL1 3537/4885TNF 192/4885MAPT 158/4885 |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | L3MBTL1 4413/4885TNF 760/4885MAPT 1177/4885 |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | L3MBTL1 2036/4885TNF 4836/4885MAPT 3157/4885 |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | ITGAV, ITGB1, ITGA1 | L3MBTL1 3897/4885TNF 1267/4885MAPT 177/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | L3MBTL1 2827/4885TNF 2167/4885MAPT 927/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | L3MBTL1 4326/4885TNF 1105/4885MAPT 864/4885 |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | L3MBTL1 3897/4885TNF 1267/4885MAPT 177/4885 |
| US-10717736-B2 | Pyrrole amides as alpha V integrin inhibitors | ITGAV, ITGB1, ITGA1 | L3MBTL1 3537/4885TNF 192/4885MAPT 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.